Nasus Pharma's NS002 Shows Promise Despite Recent Stock Decline
Nasus Pharma's recent Phase 2 study for NS002 revealed impressive results, showcasing a median threshold time of just 1.6 minutes, substantially faster than EpiPen. Despite its clinical success, the stock is down significantly, presenting a potential buying opportunity for investors looking for undervalued assets in the biotech sector.
View signal analysis